Cerevel Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CVL-871, a D1/D5 partial agonist in development for the treatment of dementia-related apathy. Fast Track is an FDA process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The designation allows for early and more frequent communication and meetings with the FDA regarding the development of CVL-871 for the treatment of dementia-related apathy. A candidate that receives Fast Track designation is also eligible for rolling review, and potentially priority review, of the marketing application.